



*In Search of Excellence*

## ORION PHARMA LIMITED

Register Office: Orion House, 153-154 Tejgaon I/ A,  
Tejgaon, Dhaka-1208

### UN-AUDITED HALF YEARLY (Q2) FINANCIAL STATEMENTS

This is for the information of all concerned that the un-audited financial statements of **Orion Pharma Limited** as on and for the **Half Yearly period ended December 31, 2018**, has been adopted by the Board of Directors in its meeting held on **January 31, 2019**. The excerpts of the Financial Statements are as follows:

	December 31, 2018	December 31, 2017
Consolidated Earnings Per Share (EPS)- Q2 :	BDT. 2.06	BDT. 2.07
Consolidated NAV per Share - Q2 (Including Revaluation Surplus) :	BDT. 73.32	BDT. 71.46
Consolidated NAV per Share - Q2 (Excluding Revaluation Surplus) :	BDT. 65.05	BDT. 63.06
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q2 :	BDT. 4.98	BDT. 4.81

The Detailed Financial Statements are also available in the Company's website:  
[www.orionpharmabd.com](http://www.orionpharmabd.com).

Sd/-  
Company Secretary

Sd/-  
Head of Finance

Sd/-  
Director

Dated: Dhaka  
January 31, 2019

Sd/-  
Managing Director

Sd/-  
Chairman